CN113226461A - 新疗法 - Google Patents

新疗法 Download PDF

Info

Publication number
CN113226461A
CN113226461A CN201980075515.9A CN201980075515A CN113226461A CN 113226461 A CN113226461 A CN 113226461A CN 201980075515 A CN201980075515 A CN 201980075515A CN 113226461 A CN113226461 A CN 113226461A
Authority
CN
China
Prior art keywords
oligonucleotide
patient
ulcerative colitis
use according
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980075515.9A
Other languages
English (en)
Chinese (zh)
Inventor
阿雷佐·扎尔加里
佩尼拉·桑德瓦尔
夏洛特·阿德米尔
托马斯·尼特尔
彼得·泽霍尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indux Pharmaceutical
Original Assignee
Indux Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indux Pharmaceutical filed Critical Indux Pharmaceutical
Publication of CN113226461A publication Critical patent/CN113226461A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201980075515.9A 2018-11-14 2019-11-14 新疗法 Pending CN113226461A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1818579.3 2018-11-14
GBGB1818579.3A GB201818579D0 (en) 2018-11-14 2018-11-14 New therapy
PCT/EP2019/081377 WO2020099585A1 (en) 2018-11-14 2019-11-14 New therapy

Publications (1)

Publication Number Publication Date
CN113226461A true CN113226461A (zh) 2021-08-06

Family

ID=64739449

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980075515.9A Pending CN113226461A (zh) 2018-11-14 2019-11-14 新疗法

Country Status (10)

Country Link
US (1) US20220218736A1 (https=)
EP (1) EP3880303A1 (https=)
JP (1) JP2022507493A (https=)
KR (1) KR20210092719A (https=)
CN (1) CN113226461A (https=)
AU (1) AU2019378077A1 (https=)
BR (1) BR112021005645A2 (https=)
CA (1) CA3118899A1 (https=)
GB (1) GB201818579D0 (https=)
WO (1) WO2020099585A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4147688A1 (en) 2021-09-09 2023-03-15 InDex Pharmaceuticals AB Enema formulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150004187A1 (en) * 2011-11-25 2015-01-01 Index Pharmaceuticals Ab Method for prevention of colectomy
WO2018206713A1 (en) * 2017-05-10 2018-11-15 Index Pharmaceuticals Ab Cobitolimod for use in the treatment of inflammatory bowel disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
GB201707503D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New Therapy 3
GB201707501D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New therapy 2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150004187A1 (en) * 2011-11-25 2015-01-01 Index Pharmaceuticals Ab Method for prevention of colectomy
WO2018206713A1 (en) * 2017-05-10 2018-11-15 Index Pharmaceuticals Ab Cobitolimod for use in the treatment of inflammatory bowel disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EUGEN MUSCH 等: "Topical Treatment with the Toll-like Receptor Agonist DIMS0150 Has Potential for Lasting Relief of Symptoms in Patients with Chronic Active Ulcerative Colitis by Restoring Glucocorticoid Sensitivity", INFLAMM BOWEL DIS, vol. 19, no. 2, 17 May 2012 (2012-05-17) *
RAJA ATREYA 等: "Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis", JOURNAL OF CROHN\'S AND COLITIS, vol. 10, no. 11, 20 May 2016 (2016-05-20) *
RAJA ATREYA 等: "Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis", DIGESTIVE AND LIVER DISEASE, vol. 50, no. 10, 22 June 2018 (2018-06-22), pages 1023 - 1024, XP085491884, DOI: 10.1016/j.dld.2018.06.010 *

Also Published As

Publication number Publication date
GB201818579D0 (en) 2018-12-26
BR112021005645A2 (pt) 2021-06-29
KR20210092719A (ko) 2021-07-26
JP2022507493A (ja) 2022-01-18
WO2020099585A1 (en) 2020-05-22
US20220218736A1 (en) 2022-07-14
AU2019378077A1 (en) 2021-04-22
EP3880303A1 (en) 2021-09-22
CA3118899A1 (en) 2020-05-22

Similar Documents

Publication Publication Date Title
US20240043847A1 (en) New therapy
AU2023237033A1 (en) Cobitolimod for use in the treatment of inflammatory bowel disease
EP3947685B1 (en) Oligonucleotide-based therapy for ulcerative colitis
CN113226461A (zh) 新疗法
WO2018206713A1 (en) Cobitolimod for use in the treatment of inflammatory bowel disease
EP4167962B1 (en) Enema formulation
CA3202097A1 (en) Cobitolimod dosage for self-administration
HK40083757A (en) Enema formulation
HK40083757B (en) Enema formulation
HK40059650A (en) Oligonucleotide-based therapy for ulcerative colitis
HK40059650B (en) Oligonucleotide-based therapy for ulcerative colitis
HK40091921A (en) Enema formulation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210806